Overview

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.
Phase:
NA
Details
Lead Sponsor:
Yunpeng Liu
Collaborator:
CSPC Ouyi Pharmaceutical Co., Ltd.
Treatments:
Capecitabine
lenvatinib